Your browser doesn't support javascript.
loading
Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics.
Haggenmüller, Sarah; Schmitt, Max; Krieghoff-Henning, Eva; Hekler, Achim; Maron, Roman C; Wies, Christoph; Utikal, Jochen S; Meier, Friedegund; Hobelsberger, Sarah; Gellrich, Frank F; Sergon, Mildred; Hauschild, Axel; French, Lars E; Heinzerling, Lucie; Schlager, Justin G; Ghoreschi, Kamran; Schlaak, Max; Hilke, Franz J; Poch, Gabriela; Korsing, Sören; Berking, Carola; Heppt, Markus V; Erdmann, Michael; Haferkamp, Sebastian; Drexler, Konstantin; Schadendorf, Dirk; Sondermann, Wiebke; Goebeler, Matthias; Schilling, Bastian; Kather, Jakob N; Fröhling, Stefan; Brinker, Titus J.
Afiliação
  • Haggenmüller S; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schmitt M; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Krieghoff-Henning E; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hekler A; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Maron RC; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wies C; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Utikal JS; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany.
  • Meier F; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hobelsberger S; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
  • Gellrich FF; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Sergon M; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Hauschild A; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • French LE; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Heinzerling L; Department of Dermatology, University Hospital (UKSH), Kiel, Germany.
  • Schlager JG; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
  • Ghoreschi K; Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida.
  • Schlaak M; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
  • Hilke FJ; Department of Dermatology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen, Germany.
  • Poch G; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
  • Korsing S; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Berking C; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Heppt MV; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Erdmann M; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Haferkamp S; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Drexler K; Department of Dermatology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen, Germany.
  • Schadendorf D; Department of Dermatology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen, Germany.
  • Sondermann W; Department of Dermatology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region Nürnberg, CCC Alliance WERA, Erlangen, Germany.
  • Goebeler M; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  • Schilling B; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  • Kather JN; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany.
  • Fröhling S; Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany.
  • Brinker TJ; Department of Dermatology, Venereology and Allergology, University Hospital Würzburg and National Center for Tumor Diseases (NCT) WERA, Würzburg, Germany.
JAMA Dermatol ; 160(3): 303-311, 2024 Mar 01.
Article em En | MEDLINE | ID: mdl-38324293
ABSTRACT
Importance The development of artificial intelligence (AI)-based melanoma classifiers typically calls for large, centralized datasets, requiring hospitals to give away their patient data, which raises serious privacy concerns. To address this concern, decentralized federated learning has been proposed, where classifier development is distributed across hospitals.

Objective:

To investigate whether a more privacy-preserving federated learning approach can achieve comparable diagnostic performance to a classical centralized (ie, single-model) and ensemble learning approach for AI-based melanoma diagnostics. Design, Setting, and

Participants:

This multicentric, single-arm diagnostic study developed a federated model for melanoma-nevus classification using histopathological whole-slide images prospectively acquired at 6 German university hospitals between April 2021 and February 2023 and benchmarked it using both a holdout and an external test dataset. Data analysis was performed from February to April 2023. Exposures All whole-slide images were retrospectively analyzed by an AI-based classifier without influencing routine clinical care. Main Outcomes and

Measures:

The area under the receiver operating characteristic curve (AUROC) served as the primary end point for evaluating the diagnostic performance. Secondary end points included balanced accuracy, sensitivity, and specificity.

Results:

The study included 1025 whole-slide images of clinically melanoma-suspicious skin lesions from 923 patients, consisting of 388 histopathologically confirmed invasive melanomas and 637 nevi. The median (range) age at diagnosis was 58 (18-95) years for the training set, 57 (18-93) years for the holdout test dataset, and 61 (18-95) years for the external test dataset; the median (range) Breslow thickness was 0.70 (0.10-34.00) mm, 0.70 (0.20-14.40) mm, and 0.80 (0.30-20.00) mm, respectively. The federated approach (0.8579; 95% CI, 0.7693-0.9299) performed significantly worse than the classical centralized approach (0.9024; 95% CI, 0.8379-0.9565) in terms of AUROC on a holdout test dataset (pairwise Wilcoxon signed-rank, P < .001) but performed significantly better (0.9126; 95% CI, 0.8810-0.9412) than the classical centralized approach (0.9045; 95% CI, 0.8701-0.9331) on an external test dataset (pairwise Wilcoxon signed-rank, P < .001). Notably, the federated approach performed significantly worse than the ensemble approach on both the holdout (0.8867; 95% CI, 0.8103-0.9481) and external test dataset (0.9227; 95% CI, 0.8941-0.9479). Conclusions and Relevance The findings of this diagnostic study suggest that federated learning is a viable approach for the binary classification of invasive melanomas and nevi on a clinically representative distributed dataset. Federated learning can improve privacy protection in AI-based melanoma diagnostics while simultaneously promoting collaboration across institutions and countries. Moreover, it may have the potential to be extended to other image classification tasks in digital cancer histopathology and beyond.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Dermatologia / Melanoma / Nevo Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Dermatologia / Melanoma / Nevo Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article